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Although the incidence of gastric cancer has fallen steadily in developed countries over the past 50 years,
outcomes in Western countries remain poor, primarily due to the advanced stage of the disease at pre-
sentation. While earlier diagnosis would help to improve outcomes for patients with gastric cancer, bet-
ter understanding of the biology of the disease is also needed, along with advances in therapy. Indeed,
progress in the treatment of gastric cancer has been limited, mainly because of its genetic complexity
and heterogeneity. As a result, there is an urgent need to apply precision medicine to the management
of the disease in order to ensure that individuals receive the most appropriate treatment. This article sug-
gests a number of strategies that may help to accelerate progress in treating patients with gastric cancer.
Incorporation of some of these approaches could help to improve the quality of life and survival for
patients diagnosed with the disease. Standardisation of care across Europe through expansion of the
European Registration of Cancer Care (EURECCA) registry – a European cancer audit that aims to improve
quality and decrease variation in care across the region – may also be expected to lead to improved out-
comes for those suffering from this common malignancy.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Gastric cancer (GC) is the fourth most common cancer world-
wide, with 980,000 cases being diagnosed in 2008, 83,000 of which
were in the European Union [1]. While dietary improvements andreduction in chronic Helicobacter pylori infection due to the use of
antibiotics have resulted in a steady fall in incidence and mortality
rates in developed countries over the past 50 years [2], outcomes
in Western countries remain poor. In Europe, overall 5-year sur-
vival from GC is around 25%, contrasting with a 70% survival rate
in Japan [3,4]. These differences reﬂect the fact that the disease is
often diagnosed at an early stage in Japan due to screening, while
in the West the disease is frequently at an advanced stage at pre-
sentation [2]. While earlier diagnosis would help to improve out-
comes for patients with GC, a better understanding of the biology
of the disease is also needed, along with advances in therapy.Pathogenesis of GC
Most GCs are gastric adenocarcinomas, which are malignant
epithelial neoplasms. However, GC is a highly heterogeneous entity
with respect to patterns of architecture and growth, cell differenti-
ation, histogenesis and molecular pathogenesis. Currently, ﬁve
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(WHO) classiﬁcation: papillary, tubular and mucinous adenocarci-
noma, poorly cohesive carcinoma (with or without signet ring
cells) and mixed carcinoma [5]. Two major types of GC were de-
scribed by Laurén – intestinal and diffuse [6]. These display differ-
ent clinicopathological proﬁles and molecular pathogenesis, and
often occur in distinct epidemiological settings [7]. Intestinal type
carcinomas generally occur in older patients and are thought to
arise through a background of chronic gastritis with progression
to intestinal metaplasia, dysplasia and gastric carcinoma [7,8]. Pro-
gression of chronic atrophic gastritis has been shown to be associ-
ated with H. pylori infection, with risk of developing GC being
dependent on strain virulence and host susceptibility [9–12]. The
diffuse type is more common in younger individuals and its path-
ogenesis is less well understood [13]. Tubular and papillary carci-
nomas (WHO classiﬁcation) roughly correspond to the intestinal
type described by Laurén, and poorly cohesive carcinomas (encom-
passing cases constituted partially or totally by signet ring cells)
correspond to the diffuse type. Rare variants account for about
10% of gastric carcinomas and a further 10% are thought to be
caused by Epstein–Barr virus [14].
Most GCs (90%) are sporadic. Familial clustering is observed in
10% of cases and only 1–3% of GCs are hereditary, comprising
hereditary diffuse gastric cancer (HDGC) [15–17] and the recently
described gastric adenocarcinoma and proximal polyposis of the
stomach (GAPPS) [18]. The molecular pathogenesis of GC is com-
plex. One of the key molecular features in sporadic cancers is the
ampliﬁcation of human epidermal growth factor receptor 2
(HER2). Around 15% of patients have HER2-positive (HER2+) GC
in clinical practice, though the proportion is higher in those with
intestinal GC (33%) and lower for individuals with diffuse disease
(6%) [19]. HER2 may also have a prognostic role in GC, though
the association remains controversial [20]. Epidermal growth fac-
tor receptor (EGFR) is also over-expressed in around 40% of GCs
[21]; however, its role in the pathogenesis of the disease is unclear.
Most HDGCs are caused by alterations of the E-cadherin gene
(CDH1) [22–24], with a minority thought to be due to a-E-catenin
[25]. E-cadherin mutations may also inﬂuence the sporadic form of
the disease and may present a target for novel cancer therapies.
The gene responsible for the recently described GAPPS syndrome
has not been identiﬁed to date [18].
The timescale of the progression of normal gastric mucosa to
gastric carcinoma is 10–20 years, yet most cases present at an
advanced stage due to the asymptomatic nature of early-stage dis-
ease, emphasising the need for earlier diagnosis to improve the
possibility of cure. However, current Western guidelines recom-
mend gastroscopy only for symptomatic patients or those with a
family history of GC, with prophylactic gastrectomy being recom-
mended for individuals with a genetic predisposition for HDGC
[23,26,27]. National screening for H. pylori to reduce GC risk has
the potential to reduce mortality, but is only likely to be cost-effec-
tive in countries with the highest incidence of the disease (e.g.
Japan).Fig. 1. Frequency of receptor tyrosine kinase (RTK)/RAS genomic alterations in
gastric cancer. Reproduced from Deng et al. [29]. Different gastric cancer subgroups
exhibiting RTK/RAS ampliﬁcation. Gastric cancers exhibiting at least one RTK/RAS
ampliﬁcation event comprise a collective 37% of the cohort analysed. EGFR,
epidermal growth factor receptor; FGFR2, ﬁbroblast growth factor receptor 2.Genomic approaches to GC heterogeneity
A range of therapies are available for the treatment of GC,
though the molecular and clinical heterogeneity associated with
the disease creates an urgent need to apply precision medicine to
management to ensure that individuals receive the most appropri-
ate drugs. In recent years, efforts have concentrated on transla-
tional research in order to identify key alterations in GC that may
represent important targets for novel therapies. These studies have
revealed a number of commonly mutated genes, of which tumour
protein 53 (TP53) is the most frequently found, though activemutations can also be identiﬁed in phosphatidylinositol-4,5-bis-
phosphate 3-kinase, catalytic subunit alpha (PIK3CA) (which gov-
erns mammalian target of rapamycin [mTOR] signalling) and
CTNNB1 (Wnt signalling) [28]. Mutations in chromatin remodelling
genes (ARID1A, MLL3 andMLL) are also common, occurring in more
than 40% of GCs. In particular, ARID1A mutations have been found
in up to 10% of tumours, often concurrent with microsatellite insta-
bility and PIK3CA-activating mutations. ARID1Amay also be a novel
tumour suppressor gene, presenting possible therapeutic opportu-
nities [28]. Receptor tyrosine kinase (RTK)/RAS ampliﬁcations (e.g.
ﬁbroblast growth factor receptor 2 [FGFR2], ERBB2/HER2, EGFR and
MET) are further frequent alterations in GC, and around 37% of pa-
tients may be potentially treatable with RTK/RAS-directed thera-
pies (Fig. 1) [29]. Additionally, DNA methylation alterations are
present in around 40% of GC tumours [30], suggesting a role for
epigenetic agents in the treatment of the disease. Activating muta-
tions in KRAS are rare in GC, though gene ampliﬁcation of wild-type
KRAS is frequent and confers a poor prognosis [29].
Recently, gene expression proﬁling using mRNA consensus clus-
tering has revealed three distinct GC subtypes – mesenchymal,
proliferative and metabolic (Table 1) [31]. It is hoped that the
distinct molecular and genetic features displayed by these new-
ly-identiﬁed subtypes and the differences in their responses to
treatment may help in the quest to develop more personalised
therapy for patients with GC. For example, the results of preclinical
studies suggest that mesenchymal-subtype GCs may be more sen-
sitive to PIK3CA/mTOR/AKT pathway targeting drugs compared
with GCs of other subtypes.Current treatment of localised GC
Surgery is the only means of cure for patients with GC and is the
treatment of choice for early-stage disease. Endoscopic resection
may be used as an alternative to surgery for early-stage tumours
if they are well differentiated (62 cm), conﬁned to the mucosa
and not ulcerated (Fig. 2) [32]. The primary goal of surgery for
localised GC is a complete resection with negative margins (R0)
[33–36]. The value of surgical expertise in GC is highlighted by
the considerable variations in GC cure rates reported in different
regions. In particular, surgery for patients with locally advanced
GC is curative in around 80% of patients in Japan, though the per-
centage is much lower in the West (up to 55%). Indeed, experience
from Japan has underlined the efﬁcacy of more extensive lymph
node dissection (D2 rather than D1) coupled with longer-term
Table 1
Biological properties and drug sensitivities of molecular subtypes of gastric cancer
identiﬁed by mRNA consensus clustering [31].
Subtype Histological
features
Associated genes Drug sensitivity
Mesenchymal Diffuse
subtype
 EMT pathways
 CSC pathways
 TGFb
 mTOR signalling
Sensitive to PI3K/
AKT/mTOR
inhibitors
Proliferative Intestinal
subtype
 Genomic instability
 TP53 mutations
 Cell cycle
 DNA replication
 Mitosis
 Copy number altera-
tions (ERBB2/HER2
and KRAS)
Unresponsive
to 5-FU
Metabolic Gastric
phenotype
 Metabolic processes
 Digestion
 Secretion
 SPEM
Increased
sensitivity to 5-
FU
CSC, cancer stem cell; EMT, epithelial mesenchymal transition; 5-FU, 5-ﬂuorouracil;
mTOR, mammalian target of rapamycin; SPEM, spasmolytic polypeptide-expressing
metaplasia; TGFb, transforming growth factor beta.
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relationship between the extent of gastrectomy and the nodal dis-
section: in a D1 total gastrectomy, stations 1, 2, 3, 4, 5, 6 and 7
should be resected while in a D2 procedure 8a, 9, 10, 11 and 12
are added. Furthermore, in a D1 subtotal gastrectomy, stations 1,
3, 4, 5, 6 and 7 are removed, with 8a, 9, 11p and 12a being added
in a D2 procedure. It is now accepted in the West that D2 dissec-
tion, performed in specialist centres, should be standard in medi-
cally ﬁt patients with resectable GC [32]. This approach has led
to an improvement in cure rates from 30% to up to 55% in the last
decade [38–41]. Minimally invasive approaches for gastric resec-
tion are being increasingly used, though it is important to ensure
that the same oncological outcome can be achieved as that possible
in open surgery, and the results of current trials comparing the two
techniques will be very informative [42,43].Fig. 2. Algorithm for the management of patients with gastric cancer recommended by t
Oncology (ESSO) and the European Society of Radiotherapy and Oncology (ESTRO).
capecitabine; PS, performance status.For patients with localised disease, better predictions of nodal
disease and prognosis are needed in order to select the most appro-
priate treatment (surgery alone or multi-modal therapy). Endo-
scopic ultrasound and computed tomography of the chest and
abdomen are currently the primary means of staging for locally ad-
vanced GC, with laparoscopy to exclude small volume peritoneal
metastatic disease in most cases [32,36]. The accuracy of these
techniques in determining preoperative stage varies from 60% to
80%. Surgery alone may be sufﬁcient for individuals with stage II
GC, though trials suggest a beneﬁt for neoadjuvant chemotherapy
in such patients and even more convincingly in stage III, improving
the ability to perform an R0 resection and reducing tumour size
and tumour burden [44–46]. In particular, perioperative epirubi-
cin, cisplatin and 5-ﬂuorouracil (5-FU) (ECF) has been shown to
signiﬁcantly improve 5-year survival versus surgery alone (36.3%
versus 23%, respectively) in patients with resectable GC [44],
resulting in this approach being adopted as the standard of care
in many European countries [32]. Nevertheless, there were limita-
tions to the design of this trial [47], and more detailed preoperative
local staging, better identiﬁcation of the patients who might bene-
ﬁt and improved trial designs are needed for future neoadjuvant
studies. Many centres now substitute 5-FU with capecitabine
(ECX), since this drug avoids the need for central line access and
has been shown to be non-inferior to 5-FU in the advanced disease
setting [48].
Adjuvant chemo(radio)therapy may also result in a survival
beneﬁt for patients with localised disease, though there is no con-
sensus as to the best approach. While the US INT-0116 trial
reported an improvement in median overall survival (OS) for adju-
vant chemoradiotherapy (36 months versus 27 months for surgery
alone) [49], inadequate surgical radicality may have led to an over-
estimation of the beneﬁt [50]. However, the results of the ongoing
Chemoradiotherapy after Induction Chemotherapy in Cancer of the
Stomach (CRITICS) trial may help to conﬁrm the beneﬁt of combi-
nation adjuvant chemoradiotherapy for localised disease. Although
individual trials failed to show a survival beneﬁt for adjuvant ther-
apy in Western patients, a recent large meta-analysis demon-
strated a survival beneﬁt for adjuvant chemotherapy in patientshe European Society for Medical Oncology (ESMO), the European Society of Surgical
Reproduced from Waddell et al. [32]. CF, cisplatin/5-ﬂuorouracil; CX, cisplatin/
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motherapy has become a standard option in Asia [52,53].
In order to improve outcomes for patients with resectable GC,
improved methods of staging incorporating prognosis and nodal
risk are needed.Current treatment options and unmet needs in advanced GC
The standard treatment for advanced GC is chemotherapy since
it provides a survival beneﬁt and improved quality of life compared
with best supportive care (BSC) alone [26,32,36,54]. Five classes of
cytotoxic agents are currently used in GC (ﬂuoropyrimidines, plat-
inums, taxanes, topoisomerase inhibitors and anthracyclines),
though the optimal combination is not well deﬁned. Nevertheless,
selection of an appropriate regimen must take into consideration
comorbidities, performance status (PS) and organ function, with
palliation being the main aim of treatment [55,56].
A number of validated doublet and triplet chemotherapy options
are available as ﬁrst-line therapy for advanced GC, though recom-
mended regimens vary between guidelines. Doublets are superior
to cytotoxic monotherapy and limited data suggest that triplets
may be more active than doublets, but with increased toxicity
[57,58]. Consequently, triplets may only be an option for younger,
ﬁt patients with normal organ functions who are more able to tol-
erate increased toxicity. Guidelines issued by the European Society
of Medical Oncology (ESMO) advocate the use of combination reg-
imens incorporating a platinum agent and a ﬂuoropyrimidine based
on the results of the Randomised ECF for Advanced and Locally Ad-
vanced Esophagogastric Cancer-2 (REAL-2) study, with capecita-
bine being preferred to 5-FU [58–61]. Other ﬁrst-line options
include irinotecan plus 5-FU and taxane-based regimens [32,62].
For HER2+ patients with advanced GC, guidelines recommend
the use of trastuzumab combined with a ﬂuoropyrimidine (5-FU
or capecitabine) plus cisplatin, based on the improved disease-free
survival (DFS) and OS demonstrated in the Trastuzumab for Gastric
Cancer (ToGA) trial [19,32,36]. These ﬁndings led to the approval of
trastuzumab by the European Medicines Agency for HER2+ pa-
tients based on an immunohistochemistry (IHC) score of 3+ or 2+
conﬁrmed by ﬂuorescence in situ hybridisation (FISH) and the reg-
imen is now the standard of care for this population. However,
quality control of molecular testing for HER2 is an important issue
and standardised protocols are needed to ensure precise identiﬁca-
tion of eligible patients [63]. The activity of trastuzumab beyond
disease progression is not well established and no data are avail-
able in the second-line, neoadjuvant or adjuvant settings, though
studies investigating neoadjuvant trastuzumab are ongoing. Trast-
uzumab is currently the only validated anti-receptor tyrosine ki-
nase-directed agent in GC, and the role of other targeted agents
is not well deﬁned. Novel agents under phase III investigation in-
clude panitumumab, cetuximab, lapatinib, onartuzumab and ril-
otumumab, though ﬁndings with these agents to date have been
disappointing [56,64–66]. Consequently, they should only be used
within a clinical trial at present [36]. Inhibition of tumour angio-
genesis has proved to be an effective treatment approach in many
cancers and a number of anti-angiogenic therapies are under
investigation in GC, including bevacizumab [67] and ramucirumab
[68,69].
Available data suggest that patients with good PS should be of-
fered second-line therapy, preferably within the setting of a clinical
trial [32,36], though data on the optimal regimen in this setting are
limited [70–73]. Irinotecan or docetaxel monotherapy are possible
options and confer a small survival beneﬁt over BSC [74–76], with
further treatment possibilities including paclitaxel, FOLFIRI (folinic
acid, 5-FU and irinotecan) or ECX [77]. Monotherapy with the
anti-vascular endothelial growth factor receptor-2 (VEGFR-2)monoclonal antibody, ramucirumab, revealed a comparable sur-
vival beneﬁt [69]. The combination of ramucirumab plus paclitaxel
has also been shown recently to confer a survival beneﬁt over pac-
litaxel alone (median OS 9.63 months versus 7.36 months, respec-
tively) [78]. It should be noted, however, that this agent is not yet
available in many countries. Patients can also be re-challenged
with the ﬁrst-line treatment if they relapse more than 3 months
after the end of treatment [32]. However, further trials are needed
to establish the best combination and sequence of cytotoxic agents
for ﬁrst- and second-line therapy, and to deﬁne the beneﬁt of
third-line treatment in GC. Additional challenges in advanced GC
include the lack of data on prognostic and predictive factors. How-
ever, retrospective analysis of the cohorts from existing studies
may help to identify biomarkers of response for different targeted
therapies. Consideration should also be given to the collection of
repeat biopsies in future early-phase studies for biomarker detec-
tion. Since patients with advanced GC are often frail with symp-
toms resulting from a high tumour burden [55,56], the toxicity of
chemotherapeutic regimens must also be taken into account, with
patient-reported outcomes and quality of life endpoints being
incorporated into future clinical trials.New cellular targets for drug treatment in GC
The molecular diversity of GC means that personalised therapy
with targeted agents is likely to play an important role in the com-
ing years. While only one targeted agent (trastuzumab) is ap-
proved in GC at present, advances in molecular biology have
identiﬁed a number of promising new targets, including EGFR,
HER3, vascular endothelial growth factor (VEGF), PI3K/mTOR,
FGFR2 and MET (Table 2) [19,29,64–66,68,69,78–80]. For example,
the EGFR and HER2 inhibitor, lapatinib, plus paclitaxel has shown
signiﬁcant efﬁcacy in HER2 3+ patients as second-line therapy in
the TyTAN study, though the trial failed to reach its primary end-
point of prolonging OS in the intent-to-treat population [66]. Other
HER2-targeted agents under investigation in the ﬁrst- and second-
line settings, respectively, include pertuzumab and trastuzumab-
DM1 (TDM1), with the anti HER2/HER4 agent neratinib also being
examined in patients with GC. In addition, HER3 may be an impor-
tant target in GC and has been associated with tumour resistance
to EGFR- and HER2-targeted agents [81,82]. A number of phase
I/II trials with HER3 monoclonal antibodies, including LJM716
and MM-12, are underway in GC. EGFR over-expression occurs in
more than 50% of tumours, suggesting that EGFR may be a promis-
ing target in GC. However, the REAL-3 (panitumumab) and Erbitux
in Combination with Xeloda and Cisplatin in Advanced Esophagic-
gastric Cancer (EXPAND) (cetuximab) studies failed to demonstrate
a beneﬁt for either of the EGFR-targeted agents currently under
investigation in an unselected population of patients with GC
[64,65].
VEGF is a key mediator in angiogenesis and its expression is
associated with more aggressive disease and poor prognosis in
GC [83,84]. A number of anti-VEGF-directed drugs are in develop-
ment, including the monoclonal antibody bevacizumab [68].
Although the phase III Avastin in Gastric Cancer Study (AVAGAST)
with bevacizumab in advanced GC did not meet the primary end-
point of extending OS, the results of a subset analysis suggest that
the agent may be of beneﬁt in certain GC subtypes (e.g. non-Asiatic
patients with diffuse or distal GC), warranting further prospective
evaluation [67,85]. These data may be explained by differences in
certain biomarkers (e.g. VEGF-A, neuropilin-1), though further
studies are needed to conﬁrm this ﬁnding [86]. The anti- VEGFR-
2 monoclonal antibody, ramucirumab, is also under investigation,
with phase II and III studies demonstrating a survival beneﬁt in
the second-line treatment of GC [69,78] A further pathway of
Table 2
Randomised phase III trials with selected targeted therapies in gastric cancer.
Therapy Study Target N Primary
endpoint
Regimen Median OS (months) ORR (%) Primary endpoint met
First line ToGA
(Bang et al., 2010) [19]
HER2 594 OS CX
CX + trastuzumab
11.1
13.8
34.5
47.3
Yes
AVAGAST
(Ohtsu et al., 2011) [68]
VEGF 774 OS CX
CX + bevacizumab
10.1
12.1
37
46
No
REAL-3
(Waddell et al., 2013) [64]
EGFR 553 OS EOC
mEOC + panitumumab
11.3
8.8
42
46
No
EXPAND
(Lordick et al., 2013) [65]
EGFR 904 PFS CX
CX + cetuximab
10.7
9.4
29
30
No
Second line GRANITE-1
(Ohtsu et al., 2013) [80]
mTOR 656 PFS Placebo
Everolimus
4.34
5.39
2.1
4.5
No
REGARD
(Fuchs et al., 2014) [69]
VEGFR-2 355 OS Placebo
Ramucirumab
3.8
5.2
2.6
3.4
Yes
TyTAN
(Bang et al., 2012) [66]
HER2 430 OS Paclitaxel
Paclitaxel + lapatinib
11
8.9
27
9
No
RAINBOW
(Wilke et al., 2014) [78]
VEGFR-2 665 OS Paclitaxel
Paclitaxel + ramucirumab
7.36
9.63
16
28
Yes
AVAGAST, Avastin in Gastric Cancer Study; CX, cisplatin/capecitabine; EGFR, epidermal growth factor receptor; EOC, epirubicin/oxaliplatin/capecitabine; EXPAND, Erbitux in
Combination with Xeloda and Cisplatin in Advanced Esophagic-gastric Cancer; HER2, human epidermal growth factor receptor 2; mEOC, modiﬁed dose EOC; mTOR,
mammalian target of rapamycin; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; REAL-3, Randomised ECF for Advanced and Locally
Advanced Esophagogastric Cancer-3; ToGA, Trastuzumab for Gastric Cancer; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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50–60% of tumours [87,88]. The mTOR inhibitor, everolimus, has
shown preclinical and early clinical efﬁcacy in GC [87,89,90],
though the phase III GRANITE-1 study assessing second-line ever-
olimus in advanced GC was negative [80], most likely because the
population was not selected according to dysregulation of the PI3K
pathway.
Inhibition of cMET is being investigated as it is over-expressed
in 75–90% and ampliﬁed in 1.5–20% of GCs [29,91,92]. Approaches
being investigated include antibodies directed at kinase ligands,
HGF (e.g. rilotumumab) or MET (e.g. onartuzumab) [93,94].
Although large phase III trials are underway to investigate these
strategies, it is unclear at present whether only patients with
ampliﬁcation will beneﬁt from cMET inhibition or whether those
with cMET protein over-expression would also beneﬁt. Since the
cMET receptor can dimerise with almost any receptor and may
be an escape mechanism for other targeted therapies, cMET inhib-
itors may also be studied in the refractory setting or in combina-
tion with other targeted agents. Further therapeutic approaches
being investigated in GC include strategies targeting the immune
system, the Wnt/b-catenin pathway and other stem cell-associated
pathways.
Selection of the right patients for targeted therapy is a key chal-
lenge in GC in order to improve response to treatment, along with
linkage of preclinical research on the molecular patterns in the dis-
ease to clinical practice. A further issue is that the molecular proﬁle
of tumours is likely to change under the stress of treatment sug-
gesting that biopsies should be repeated following relapse and/or
between ﬁrst- and second-line therapies. However, advances in li-
quid biopsies are needed in this regard as repeat tumour biopsies
can be hampered by difﬁcult localisation (e.g. peritoneal metasta-
ses) and other obstacles in many patients. Furthermore, blood
must be treated within 20 min for analysis of circulating DNA at
present due to the presence of degrading enzymes. Further re-
search is needed, therefore, to determine the optimal methods
for stabilising, freezing and thawing blood.
Issues and new approaches in drug development for GC
Although effective perioperative chemotherapy is available for
GC, locoregional control remains an issue, with 20–25% of resected
tumours developing locoregional relapse. For this reason, a
number of studies have investigated the efﬁcacy of combiningchemotherapy and radiotherapy, either perioperatively or
postoperatively [49,95–97]. While such approaches may improve
response rates, the results of ongoing phase III studies such as
the Trial Of Preoperative Therapy for Gastric and Esophagogastric
Junction Adenocarcinoma (TOPGEAR) and CRITICS are needed to
determine whether they can improve survival. Further improve-
ments in perioperative treatment require strategies to improve
the efﬁcacy of chemotherapy, including its combination with tar-
geted therapy. For example, the combination of trastuzumab and
pertuzumab with chemotherapy may be an option for patients
with HER2+ GC, though recruitment may be an issue for such a trial
as HER2+ is relatively uncommon (<15% of GCs). The combination
of chemotherapy with the anti-angiogenic drug, bevacizumab, is
also being studied in the STO3 trial, with initial ﬁndings suggesting
that the agent was well tolerated, though cardiac events were
increased by around 10% [67].
A further challenge in the treatment of GC is the need for re-
search into the optimal management for those with limited meta-
static disease as current strategies are not well established.
Nevertheless, the results of the ongoing 5-FU, oxaliplatin, leucovo-
rin and docetaxel (FLOT)-3 study, which aims to determinewhether
prognosis for such patients may be improved by combining chemo-
therapy and surgical approaches, may help to resolve this issue
[98]. Treatment of patients with diffuse-type GC is also difﬁcult
and further studies are needed. It should be noted, however, that
trials in this population will require reliable and validated histopa-
thological diagnosis along with good collaborative networks in or-
der to recruit sufﬁcient numbers of patients. The development of
collaborative networks must also be considered for screening pa-
tients for rare alterations in GC (e.g. ampliﬁcation of cMET, FGFR
and others) in order to accelerate progress in drug development.
Further measures to speed up drug development include adoption
of novel endpoints such as histopathological tumour regression
[99], though its assessment requires good quality assurance and
centralised pathology. The efﬁciency of future trials in GC may also
be improved by the inclusion of metabolic imaging with ﬂuorode-
oxyglucose-positron emission tomography (FDG-PET) to detect
early response to treatment [98,100,101].
Towards provision of better GC healthcare services in Europe
Surgery for GC is complex and requires training to ensure
standardisation, along with multidisciplinary team effort. The
F. Lordick et al. / Cancer Treatment Reviews 40 (2014) 692–700 697importance of specialist care for patients with GC has been high-
lighted by the Dutch Gastric Cancer Trial, which demonstrated that
outcomes can be improved by training surgeons more effectively
[41,102]. In this study, surgical quality control was enhanced by
ensuring that all surgeons received expert training, with all D1
and D2 resections being supervised. After a 15-year follow-up,
mortality was signiﬁcantly lower for D2 versus D1 resection, lead-
ing to D2 being recommended as the standard approach for resect-
able GC in the Netherlands. Outcomes can also be improved by
centralisation of care, selecting centres with the best results and
the highest patient volumes (P20 cases/year), as well as by audit-
ing the performance of hospitals and surgeons. Audits undertaken
to date within a number of European countries (e.g. UK, Denmark,
Sweden and the Netherlands) have identiﬁed a signiﬁcant inverse
relationship between patient volume and 30-day mortality. How-
ever, considerable variation was seen between both countries
and hospitals, underlining the need for a uniform European regis-
try [103].
The European Registration of Cancer Care (EURECCA), initiated
through collaboration between seven European countries (Den-
mark, France, Ireland, the Netherlands, Poland, Sweden and the
UK), is designed to meet this need and aims to compare surgicalTable 3
Summary of the challenges in gastric cancer and proposals for addressing them.
Challenge Pr
Only one targeted agent has been approved for ﬁrst-line treatment in GC to date
(trastuzumab) and only one agent has been successful as second-line
treatment (ramucirumab) primarily due to the genetic complexity and
heterogeneity of the disease
Cure rates following surgery for resectable GC in the West (up to 55%) lag behind
those in Japan (80%)
The optimal treatment (surgery alone or multi-modal therapy) for early-stage
disease has not been established and the neoadjuvant approach is not
universally accepted as standard
Treatment for advanced GC is challenging and the optimal combination of
chemotherapy (doublets, triplets or sequence) is not well deﬁned
Locoregional control after resection remains an issue, with 20–25% of resected GC
tumours developing locoregional relapse
EURECCA, European Registration of Cancer Care; CRITICS, Chemoradiotherapy after Ind
epidermal growth factor receptor 2.outcomes, resection rates and patterns of care for patients with
GC in Europe [104,105]. The registry will employ a European can-
cer audit to improve quality and decrease variation in care across
the region by identifying and spreading best practices, monitoring
outcomes and developing guidelines. It is hoped that centralisation
and auditing of services through EURECCA will go some way to im-
prove long-term outcomes for patients with GC throughout the
region.Summary
Although the incidence of GC has fallen in developed countries
in recent years, advances in the treatment of the disease have been
limited, primarily due to its genetic complexity and heterogeneity.
This group of authors has suggested a number of strategies that
may help to accelerate progress in treating patients with the con-
dition, as summarised in Table 3. Incorporation of some of the ap-
proaches described in this article could help to improve quality of
life and survival for patients with GC. Standardisation of care
across Europe through expansion of the EURECCA registry may also
be expected to lead to improved outcomes for those suffering from
this common malignancy.oposal for addressing
 Strategies aimed at applying precision medicine to management to ensure that
individuals receive the most appropriate drugs
 Use of translational research to identify key mutations may reveal important
targets for novel therapies
 Standardised protocols for HER2 testing to ensure precise identiﬁcation of eli-
gible patients and improve response rates
 Repeat biopsies to examine changes in the molecular proﬁle of tumours taking
place under the stress of treatment
 Surgery for GC performed in specialist centres by experienced surgeons
 Adoption of D2 dissection as the standard of care for medically ﬁt patients with
resectable GC
 Standardisation of D2 dissection
 Auditing of the performance of hospitals and individual surgeons, with moni-
toring being performed by the medical profession to avoid surgeons only
undertaking lower-risk cases
 Expansion of the EURECCA registry, which seeks to improve quality and
decrease variation in care across Europe by identifying and spreading best prac-
tices and monitoring outcomes
 Future neoadjuvant studies require more detailed preoperative local staging,
better identiﬁcation of the patients who might beneﬁt and improved trial
design
 Results from ongoing ST03 and CRITICS trials to conﬁrm the beneﬁt of addi-
tional anti-angiogenic therapy or radiotherapy for localised disease
 Improved methods of staging are needed, incorporating prognosis and nodal
risk to improve outcomes
 Triplets should be considered only for younger, ﬁt patients with normal organ
functions who are more able to tolerate increased toxicity
 Further trials are needed to establish the best combination and sequence of
cytotoxic agents in ﬁrst- and second-line, and to deﬁne the beneﬁt of third-line
treatment in GC
 Retrospective analysis of the cohorts from existing studies, prospective data
and biomaterial collection to identify biomarkers of response for different tar-
geted therapies
 Collection of repeat biopsies in future early-phase studies for biomarkers
detection
 Incorporation of patient-reported outcomes and quality of life endpoints into
future clinical trials
 Results of ongoing phase III studies (e.g. TOPGEAR and CRITICS) to determine
whether combining chemotherapy and radiotherapy (perioperatively or post-
operatively) can improve survival
 Strategies designed to improve the efﬁcacy of chemotherapy, including its com-
bination with targeted therapy
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